Knights of Columbus Asset Advisors LLC Has $8.95 Million Holdings in Stryker Corporation $SYK

Knights of Columbus Asset Advisors LLC lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 28.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,210 shares of the medical technology company’s stock after selling 9,640 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Stryker were worth $8,950,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Norges Bank bought a new stake in shares of Stryker in the 2nd quarter worth $1,882,173,000. Alliancebernstein L.P. grew its position in shares of Stryker by 307.6% during the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock valued at $2,214,146,000 after acquiring an additional 4,223,366 shares during the period. Corient Private Wealth LLC increased its stake in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. ABN AMRO Bank N.V. bought a new position in Stryker during the second quarter valued at $191,047,000. Finally, Vanguard Group Inc. raised its stake in shares of Stryker by 1.3% in the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock valued at $13,253,831,000 after buying an additional 440,607 shares during the period. Institutional investors own 77.09% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat — Stryker posted Q4 adjusted EPS $4.47 (vs. $4.40 consensus) and revenue $7.17B, with organic sales up ~11% and adjusted operating margin expanding 100 bps, signaling continued top‑line momentum and operating leverage. Stryker reports 2025 operating results and 2026 outlook
• Positive Sentiment: Raised outlook/supportive commentary — Management now guides 2026 organic net sales growth of 8.0%–9.5% and adjusted EPS $14.90–$15.10 and indicated modestly favorable pricing and FX, prompting firms to keep/confirm Buy ratings. Reuters notes management raised its profit forecast tied to strong capital and implant demand. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analyst support — Multiple shops (Needham, Piper Sandler and others) reiterated Buy/Overweight ratings after the results, citing sustained double‑digit growth in key MedSurg/Neuro businesses and improved margins. Stryker: Sustained Double-Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: FY26 EPS range roughly in line with consensus — the $14.90–$15.10 range centers near Street estimates (consensus ~14.96). That calmingly conservative guidance reduces upside surprise potential and helps explain muted share reaction despite the beat.
• Neutral Sentiment: Earnings call / details available — full Q4 earnings call transcript and company presentation provide more color on product momentum, capital demand and margin drivers for investors reviewing catalysts. Stryker Q4 2025 Earnings Call Transcript
• Negative Sentiment: Tariff/regulatory risks flagged — some analysts and the company note potential 2026 tariff headwinds and geopolitical/regulatory risks that could pressure margins or growth in certain markets if they materialize.
• Negative Sentiment: Large insider selling noted by data providers — recent public filings and data aggregators show substantial insider share sales over the past 6 months, which can amplify sell‑side pressure or signal near‑term positioning changes. QuiverQuant summary & insider activity
• Negative Sentiment: Product/segment items — notable declines or one‑time items (e.g., a material drop in spinal implants year/quarter comparisons and earlier goodwill/impairment charges) remain on the P&L and are potential longer‑term headwinds for parts of Orthopaedics. Stryker reports 2025 operating results and 2026 outlook

Stryker Price Performance

SYK stock opened at $354.39 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. The firm has a market cap of $135.52 billion, a P/E ratio of 46.57, a P/E/G ratio of 2.29 and a beta of 0.89. The firm’s fifty day moving average is $359.38 and its 200 day moving average is $371.95. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The firm had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same quarter in the prior year, the firm posted $4.01 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. Research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. This is a positive change from Stryker’s previous quarterly dividend of $0.84. Stryker’s dividend payout ratio is 46.25%.

Insider Buying and Selling at Stryker

In related news, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 522,118 shares of company stock valued at $185,381,932. 5.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on SYK shares. Barclays lifted their price objective on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Evercore ISI set a $390.00 price target on shares of Stryker in a research report on Monday, January 5th. Piper Sandler reaffirmed an “overweight” rating on shares of Stryker in a report on Tuesday. Sanford C. Bernstein increased their target price on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Finally, Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a research report on Tuesday, January 6th. Twelve investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $425.94.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.